General Information of DTT (ID: TTOU65C)

DTT Name Tyrosine-protein kinase SYK (SYK) DTT Info
Gene Name SYK

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [1]
------------------------------------------------------------------------------------
16 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fostamatinib disodium DM3274D Thrombocytopenia 3B64 Phase 3 [2]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [3]
Cevidoplenib DM9QU5G Rheumatoid arthritis FA20 Phase 2 [4]
GS-9876 DM9Q2B6 Cutaneous lupus erythematosus EB5Z Phase 2 [5]
GS-9973 DMKWCTR Acute myeloid leukaemia 2A60 Phase 2 [6]
TAK-659 DMJH3U0 Diffuse large B-cell lymphoma 2A81 Phase 2 [7]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [8]
HM43239 DMV1SDA Acute myeloid leukaemia 2A60 Phase 1/2 [9]
BI 894416 DMJ8EAJ Asthma CA23 Phase 1 [10]
GSK2646264 DMQOM5V Cutaneous lupus erythematosus EB5Z Phase 1 [11]
HMPL-523 DMXZ1A8 Non-hodgkin lymphoma 2B33.5 Phase 1 [12]
PRT-062607 DMBL7CW Chronic lymphocytic leukaemia 2A82.0 Phase 1 [13]
PRT6207 DMP5CLY Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
PUR1800 DM6H10N Chronic obstructive pulmonary disease CA22 Phase 1 [14]
SKI-O-703 DMTSKXR Rheumatoid arthritis FA20 Phase 1 [5]
tamatinib DMGANIC Solid tumour/cancer 2A00-2F9Z Clinical trial [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Clinical Trial Drug(s)
4 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrimidopyridazinone derivative 1 DM32N7D N. A. N. A. Patented [16]
Pyrimidopyridazinone derivative 2 DMD1RT0 N. A. N. A. Patented [16]
Pyrrolo-pyrazine derivative 3 DMLM6DT N. A. N. A. Patented [17]
Pyrrolo-pyrazine derivative 4 DMD1S92 N. A. N. A. Patented [17]
------------------------------------------------------------------------------------
2 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-343 DMEJNM1 Asthma CA23 Discontinued in Phase 2 [18]
PF-3526299 DMMU1W3 Asthma CA23 Discontinued in Phase 1 [19]
------------------------------------------------------------------------------------
10 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CG-103065 DMGW9QL Solid tumour/cancer 2A00-2F9Z Investigative [1]
DNX-2000 DMC5RL7 Autoimmune diabetes 5A10 Investigative [1]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [20]
K00592a DM1RP5Q Discovery agent N.A. Investigative [21]
N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide DMUD85N Discovery agent N.A. Investigative [22]
PMID17600705C23 DMJFOGW Discovery agent N.A. Investigative [23]
PMID23312943C21 DMOJ8QR Discovery agent N.A. Investigative [24]
PRT-060318 DMQPEA7 Thrombosis DB61-GB90 Investigative [1]
SBB007833 DMU8KGB Discovery agent N.A. Investigative [25]
VRT-750018 DMFT49S Allergy 4A80-4A85 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Investigative Drug(s)
Molecule Interaction Atlas

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Company report (Portola Pharmaceuticals)
4 A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models. Clin Exp Immunol. 2023 Mar 8;211(1):31-45.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
7 J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
8 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
9 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
10 Synthesis of BI 894416 and BI 1342561, two potent and selective spleen tyrosine kinase inhibitors, labeled with carbon 14 and with deuterium. J Labelled Comp Radiopharm. 2023 Apr-May;66(4-6):155-168.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical pipeline report, company report or official report of Hutchison MediPharma.
13 Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243.
14 Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
15 Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9.
16 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
17 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
18 A novel Syk kinase inhibitor suitable for inhalation: R-343(. Expert Opin Ther Pat. 2009 Oct;19(10):1469-72.
19 Pipeline report of RIGEL Pharmaceuticals.
20 Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6.
21 Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51.
22 Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin ... J Med Chem. 2001 Feb 1;44(3):441-52.
23 N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
24 Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5.
25 Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11.